Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir


The invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TDF, significantly increases the level of protection against HIV transmission.

Potential Commercial Applications: Competitive Advantages:
  • Oral, prophylactic delivery of combination drugs to inhibit HIV infection
 


Development Stage:
  • In vivo data available (animal)
  • In vivo data available (human)


Inventors:

Walid Heneine (CDC)  ➽ more inventions...

Thomas Folks (CDC)  ➽ more inventions...

Robert Janssen (CDC)  ➽ more inventions...

Ronald Otten (CDC)  ➽ more inventions...

Jose Garcia Lerma (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,937,191 issued 2018-04-10
U.S. Pat: 10,335,423 issued 2019-07-02
U.S. Pat: 9,044,509 issued 2015-06-02
U.S. Pat: 9,579,333 issued 2017-02-28
PCT Application No. PCT/US2007/002926
US Application No. 14/679,887
US Application No. 16/413,381
US Application No. 16/808,135
US Application No. 16/808,120
US Application No. 16/808,089
and various international issued patents/pending applications

Publications:
Garcia-Lerma J, et al. PMID 18254653
Garcia-Lerma J, et al. PMID 20371467

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-195-2013-0
Updated: Sep 25, 2014